Is the biotech bubble bursting? Maybe -- but certainly not for every biotech stock. Three of the biggest of this week experienced gains of at least 17%.
One benefited from positive preliminary data from an early-stage clinical trial. Another surged after an unexpected acquisition by a larger company made the news. And the third stock looks to be rebounding from a big sell-off over the past couple of months.
Which stocks made this week's list of the most humongous performers in all of health care? Find out by watching the following slideshow.